McKesson raises fiscal 2027 EPS guidance and closes $2.25B Precision Medicine Group deal
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: McKesson (MCK) Q2 fiscal 2027 MANAGEMENT VIEW * "Second quarter revenues increased 8% with growth across all segments, while adjusted earnings per diluted share increased 18% year-over-year." (CEO & Chairman Brian Tyler) * "As a result of our strong…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA major drug distributor raising full-year guidance and closing a sizable acquisition can move the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01McKesson raises fiscal 2027 adjusted EPS guidance to $45.60-$46.40 from $44.20-$45.
- 02Second-quarter revenues rose 8%, while adjusted EPS grew 18% year over year.
- 03The company closed its $2.25B acquisition of Precision Medicine Group.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets